3D Bio: 3DBio Therapeutics Announces Appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to Board of Directors
NEW YORK, April 2, 2019 /PRNewswire/ -- 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced the appointment of Sol Barer, Ph.D. and Kevin Slawin, M.D. to its Board of Directors. Dr. Barer
Read full article »
3DBio is a regenerative medicine company solving medical challenges with custom-engineered 3D-bioprinted living implants.
Read more